Zacks Investment Research downgraded shares of Seelos Therapeutics (NASDAQ:SEEL) from a buy rating to a hold rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company’s product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States. “

SEEL has been the subject of several other research reports. Benchmark began coverage on shares of Seelos Therapeutics in a research note on Thursday, November 14th. They issued a buy rating and a $4.00 price objective for the company. HC Wainwright increased their price objective on shares of Seelos Therapeutics from $2.00 to $4.00 and gave the company a buy rating in a research note on Monday, November 18th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $4.44.

Shares of SEEL remained flat at $$1.24 on Tuesday. 298,620 shares of the company were exchanged, compared to its average volume of 495,858. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.93 and a quick ratio of 2.93. Seelos Therapeutics has a 12 month low of $0.72 and a 12 month high of $7.49. The company has a fifty day moving average of $1.36 and a two-hundred day moving average of $1.28.

Seelos Therapeutics (NASDAQ:SEEL) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.01). The business had revenue of $0.38 million for the quarter. As a group, analysts expect that Seelos Therapeutics will post -3.63 EPS for the current year.

A number of large investors have recently bought and sold shares of the business. Northern Trust Corp bought a new position in shares of Seelos Therapeutics during the 2nd quarter valued at approximately $25,000. Citadel Advisors LLC bought a new position in Seelos Therapeutics in the 2nd quarter valued at $29,000. Virtu Financial LLC bought a new position in Seelos Therapeutics in the 3rd quarter valued at $68,000. Wedbush Securities Inc. boosted its holdings in Seelos Therapeutics by 412.7% in the 3rd quarter. Wedbush Securities Inc. now owns 82,028 shares of the company’s stock valued at $75,000 after purchasing an additional 66,028 shares during the period. Finally, A.R.T. Advisors LLC boosted its holdings in Seelos Therapeutics by 371.5% in the 2nd quarter. A.R.T. Advisors LLC now owns 52,342 shares of the company’s stock valued at $115,000 after purchasing an additional 41,242 shares during the period. Hedge funds and other institutional investors own 12.37% of the company’s stock.

Seelos Therapeutics Company Profile

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients.

See Also: How does a dividend reinvestment plan work?

Get a free copy of the Zacks research report on Seelos Therapeutics (SEEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.